Chronic kidney disease (CKD) in adults, with specified ranges of eGFR and albuminuria (UACR), irrespective of T2DM status; background SGLT2i dapagliflozin 10 mg as GDMT.
Conditions
Brief summary
Time to first occurrence of any component of the composite of: ≥50% sustained decline in eGFR, end-stage kidney disease (ESKD; sustained eGFR <10 mL/min/1.73 m2, chronic dialysis, or renal transplant), or all-cause mortality.
Detailed description
Time to first occurrence of composite of ≥50% sustained decline in eGFR, ESKD, or CV and renal death., Time to composite of all-cause mortality, MI, or stroke., Time to 3-point MACE (CV death, MI, stroke)., Time to all-cause mortality., Time to CV death., Time to first occurrence of any component of pure renal composite: ≥50% sustained decline in eGFR, ESKD, or renal death., Time to composite of CV death or hospitalization for HF (hHF)., Time to composite of CV death MI, stroke, or HF hospitalizations., Time to all-cause hospitalization.
Interventions
Sponsors
AstraZeneca AB
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to first occurrence of any component of the composite of: ≥50% sustained decline in eGFR, end-stage kidney disease (ESKD; sustained eGFR <10 mL/min/1.73 m2, chronic dialysis, or renal transplant), or all-cause mortality. | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to first occurrence of composite of ≥50% sustained decline in eGFR, ESKD, or CV and renal death., Time to composite of all-cause mortality, MI, or stroke., Time to 3-point MACE (CV death, MI, stroke)., Time to all-cause mortality., Time to CV death., Time to first occurrence of any component of pure renal composite: ≥50% sustained decline in eGFR, ESKD, or renal death., Time to composite of CV death or hospitalization for HF (hHF)., Time to composite of CV death MI, stroke, or HF hospitalizations., Time to all-cause hospitalization. | — |
Outcome results
None listed